Form 4: ATAI Life Sciences CFO Acquires Stock Options

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., reports the acquisition of stock options.

Summary

• Anne Nagengast Johnson, the Chief Financial Officer of ATAI Life Sciences N.V. (ATAI), filed a Form 4 with the SEC.
• The filing reports the acquisition of 757,915 stock options on March 3, 2025, at an exercise price of $1.50.
• These options vest as to 25% on January 1, 2026, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
• The options expire on March 3, 2035.
• Following the transaction, Johnson directly owns 757,915 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant itself is a positive for the executive, but doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Compass Pathways and MindMed also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could potentially incentivize the CFO to improve company performance, benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates